# Aptevo Therapeutics

Aptevo Therapeutics is an other based in Seattle, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Seattle, United States
- **Region:** North America
- **Address:** Seattle, WA, United States
- **Founded:** 2016
- **Assets under management:** Undisclosed
- **Website:** aptevotherapeutics.com

## Regulatory record

- **Reports private funds:** No

## About

Aptevo Therapeutics was formed in 2016 as a spin-out from Emergent BioSolutions, taking with it bispecific antibody programs in oncology. The company is publicly traded on the NASDAQ, not structured as a family office. The firm's drug discovery work centers on the ADAPTIR and ADAPTIR-FLEX platforms, which generate bispecific antibodies designed to co-engage immune cells with tumor targets. Its lead candidate is apotacrit, a bispecific antibody targeting CD3 and the tumor antigen CD37, currently in a Phase 2 trial for relapsed/refractory B-cell non-Hodgkin lymphoma. Another candidate, APVO603, targets 5T4 and is at an earlier preclinical stage. Development has faced challenges: a Phase 2 trial of former candidate ACV-1 (targeting cancer stem cells) was halted in 2021 after interim futility analysis. Total AUM is not applicable — the firm is a public biotech micro-cap, not a capital allocator. The company's annual R&D spend is typically under $20 million (per SEC filings, 2023). It has not disclosed assets under management as it is a drug developer, not an investment vehicle. Aptevo is structurally distinct from family offices in that it is a public company with a market capitalization typically under $50 million, a development-stage biotech. It raises capital through equity offerings and grants rather than managing long-term capital pools. There is no succession or multigenerational governance structure.

## Sectors

- Biotech
- Oncology
- Immunotherapy

## Questions

### Who makes investment decisions at Aptevo Therapeutics?

Aptevo Therapeutics is a publicly traded biotech company, not a family office. Its investment decisions are made by its CEO and board of directors, with strategic input from its scientific advisory board. The company does not have a CIO or deployment team.

### What is the primary drug platform of Aptevo?

Aptevo has two proprietary drug platforms: ADAPTIR and ADAPTIR-FLEX. These are bispecific antibody technologies that enable simultaneous targeting of two different antigens, primarily used to activate the immune system against cancer cells.

### How is Aptevo structured as a company?

Aptevo is a publicly traded clinical-stage biotech incorporated in Delaware, trading on the NASDAQ. It is not structured as a family office or asset manager. It does not have alternative investment vehicles, co-investment programs, or fund commitments. Its operations are funded through public offerings and licensing.

### Where does the underlying capital for Aptevo come from?

Aptevo is a public company listed on the NASDAQ. Its capital comes from public equity markets, including at-the-market offerings and private placements. It is not associated with a family fortune or endowment. The company does not manage outside capital; it operates as a corporate entity.

## Related profiles

- [Noble Plains Uranium Corp.](https://altss.com/profile/noble-plains-uranium-corp)
- [Alaunos Therapeutics, Inc.](https://altss.com/profile/alaunos-therapeutics-inc)

---

Last updated: 2026-07-10T19:43:12.000Z

Canonical page: https://altss.com/profile/aptevo-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology